Boehringer Ingelheim

Replying to @willsemi

Continuous OSD manufacturing is gaining regulatory traction. Quality by design is essential.

Replying to @estee

Fragment-based drug discovery by X-ray crystallography revealed a new binding pocket.

Replying to @avantor

Glycan analysis is a key CQA. Our HILIC data aligns well with yours.

Replying to @chipscreen

The crystalline form showed no polymorphic conversion under accelerated stability conditions.